Details of the Drug Combination

General Information of Drug Combination (ID: DCIYFBD)

Drug Combination Name
Azithromycin Tetracycline
Indication
Disease Entry Status REF
Trachoma Phase 3 [1]
Component Drugs Azithromycin   DMS6UOE Tetracycline   DMZA017
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Azithromycin
Disease Entry ICD 11 Status REF
Acute gonococcal cervicitis N.A. Approved [2]
Bronchitis CA20 Approved [3]
Chancroid N.A. Approved [2]
Mycoplasma pneumoniae pneumonia N.A. Approved [2]
Staphylococcus aureus infection N.A. Approved [2]
Streptococcal pneumonia N.A. Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [4]
Pneumonia caused by chlamydia N.A. Investigative [2]
Indication(s) of Tetracycline
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [5]
Actinomycosis N.A. Approved [5]
Acute gonococcal cervicitis N.A. Approved [5]
Acute gonococcal epididymo-orchitis N.A. Approved [5]
Bacterial infection 1A00-1C4Z Approved [6]
Bronchitis CA20 Approved [5]
Brucellosis N.A. Approved [5]
Lymphogranuloma venereum N.A. Approved [5]
Ornithosis N.A. Approved [5]
Pneumonia CA40 Approved [5]
Q fever N.A. Approved [5]
Relapsing fever N.A. Approved [5]
Rickettsialpox N.A. Approved [5]
Rocky mountain spotted fever N.A. Approved [5]
Syphilis N.A. Approved [5]
Trachoma N.A. Approved [5]
Typhus N.A. Approved [5]
Urinary tract infection GC08 Approved [5]
Yaws N.A. Approved [5]
Pelvic inflammatory disease GA05 Investigative [5]
Sinusitis CA0A.Z Investigative [5]
Tetracycline Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) TTQ8KVI F4NA87_STAAU Binder [8]
------------------------------------------------------------------------------------
Tetracycline Interacts with 5 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [10]
Organic anion transporter 2 (SLC22A7) DT0OC1Q S22A7_HUMAN Substrate [11]
Organic anion transporter 3 (SLC22A8) DTVP67E S22A8_HUMAN Substrate [11]
Organic anion transporter 4 (SLC22A11) DT06JWZ S22AB_HUMAN Substrate [11]
------------------------------------------------------------------------------------
Tetracycline Interacts with 44 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Solute carrier family 22 member 7 (SLC22A7) OTKTNH1W S22A7_HUMAN Increases Transport [12]
Organic anion transporter 3 (SLC22A8) OT8BY933 S22A8_HUMAN Increases Uptake [11]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Decreases Activity [13]
Glutathione S-transferase Mu 3 (GSTM3) OTLA2WJT GSTM3_HUMAN Decreases Activity [13]
Nuclear protein 1 (NUPR1) OT4FU8C0 NUPR1_HUMAN Increases Expression [7]
Alpha-1-antichymotrypsin (SERPINA3) OT9BP2S0 AACT_HUMAN Increases Expression [7]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Increases Expression [7]
Inhibin beta E chain (INHBE) OTOI2NYG INHBE_HUMAN Increases Expression [7]
AP-1 complex subunit sigma-1A (AP1S1) OTQ2H8DN AP1S1_HUMAN Decreases Expression [7]
Transgelin (TAGLN) OTAEZ0KP TAGL_HUMAN Decreases Expression [7]
Fibronectin type III domain-containing protein 4 (FNDC4) OTOQK0WK FNDC4_HUMAN Increases Expression [7]
Protein DEPP1 (DEPP1) OTB36PHJ DEPP1_HUMAN Increases Expression [7]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [14]
Alternative prion protein (PRNP) OTE85L1Q APRIO_HUMAN Affects Binding [15]
Claudin-11 (CLDN11) OTNN6UTL CLD11_HUMAN Decreases Expression [16]
72 kDa type IV collagenase (MMP2) OT5NIWA2 MMP2_HUMAN Decreases Activity [17]
Stromelysin-1 (MMP3) OTGBI74Z MMP3_HUMAN Decreases Activity [17]
Integrin alpha-5 (ITGA5) OT3RCI67 ITA5_HUMAN Increases Expression [16]
Insulin-like growth factor-binding protein 1 (IGFBP1) OT6UQV2K IBP1_HUMAN Increases Expression [18]
Integrin alpha-M (ITGAM) OTAG6HWU ITAM_HUMAN Decreases Expression [16]
DNA topoisomerase 2-alpha (TOP2A) OT6LPS08 TOP2A_HUMAN Decreases Expression [19]
Integrin alpha-L (ITGAL) OTCUQAIS ITAL_HUMAN Decreases Expression [16]
Neutrophil collagenase (MMP8) OTZXH19L MMP8_HUMAN Decreases Activity [17]
Integrin alpha-3 (ITGA3) OTBCH21D ITA3_HUMAN Decreases Expression [16]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [20]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Phosphorylation [20]
Sterol regulatory element-binding protein 1 (SREBF1) OTWBRPAI SRBP1_HUMAN Increases Expression [18]
Collagenase 3 (MMP13) OTY8BZIE MMP13_HUMAN Decreases Activity [17]
Gap junction alpha-8 protein (GJA8) OTZCPRKD CXA8_HUMAN Decreases Expression [16]
Microsomal triglyceride transfer protein large subunit (MTTP) OTNUVSDT MTP_HUMAN Decreases Expression [18]
Claudin-15 (CLDN15) OT9K0KI7 CLD15_HUMAN Decreases Expression [16]
Claudin-6 (CLDN6) OTEN8ID2 CLD6_HUMAN Decreases Expression [16]
Claudin-8 (CLDN8) OT7IIWXG CLD8_HUMAN Decreases Expression [16]
Claudin-2 (CLDN2) OTRF3D6Y CLD2_HUMAN Decreases Expression [16]
Claudin-10 (CLDN10) OT2CVAKY CLD10_HUMAN Decreases Expression [16]
Peroxisomal bifunctional enzyme (EHHADH) OTBAAHL5 ECHP_HUMAN Decreases Expression [18]
Diacylglycerol O-acyltransferase 2 (DGAT2) OTE5PDD0 DGAT2_HUMAN Increases Expression [20]
Neurogenic locus notch homolog protein 4 (NOTCH4) OTBCHB61 NOTC4_HUMAN Decreases Expression [16]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Increases Expression [21]
Gap junction delta-2 protein (GJD2) OTDR288R CXD2_HUMAN Decreases Expression [16]
Neurogenic locus notch homolog protein 3 (NOTCH3) OTMVVA7F NOTC3_HUMAN Decreases Expression [16]
Solute carrier family 22 member 6 (SLC22A6) OTKRCBVM S22A6_HUMAN Increases Export [11]
ATP-binding cassette sub-family C member 4 (ABCC4) OTO27PAL MRP4_HUMAN Increases Transport [22]
Organic anion transporter 7 (SLC22A9) OTO4BJCC S22A9_HUMAN Increases Export [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 44 DOT(s)

References

1 ClinicalTrials.gov (NCT02754583) Sanitation, Water, and Instruction in Face-washing for Trachoma I/II
2 Azithromycin FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 065511.
4 ClinicalTrials.gov (NCT04332107) Azithromycin for COVID-19 Treatment in Outpatients Nationwide. U.S. National Institutes of Health.
5 Tetracycline FDA Label
6 How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
7 Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
8 The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88.
9 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
10 Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
11 Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
12 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
13 Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. Int J Cancer. 2002 Feb 10;97(5):700-5.
14 A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos. 2008 Aug;36(8):1689-97.
15 Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol. 2000 Jul 28;300(5):1309-22. doi: 10.1006/jmbi.2000.3840.
16 Effects of residual levels of tetracycline on the barrier functions of human intestinal epithelial cells. Food Chem Toxicol. 2017 Nov;109(Pt 1):253-263. doi: 10.1016/j.fct.2017.09.004. Epub 2017 Sep 4.
17 Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases. Bioorg Med Chem. 2007 Mar 15;15(6):2368-74. doi: 10.1016/j.bmc.2007.01.026. Epub 2007 Jan 19.
18 Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis. Toxicol Appl Pharmacol. 2016 Jul 1;302:1-9. doi: 10.1016/j.taap.2016.04.007. Epub 2016 Apr 16.
19 Old drug, new target: ellipticines selectively inhibit RNA polymerase I transcription. J Biol Chem. 2013 Feb 15;288(7):4567-82. doi: 10.1074/jbc.M112.411611. Epub 2013 Jan 4.
20 Increased hepatic Fatty Acid uptake and esterification contribute to tetracycline-induced steatosis in mice. Toxicol Sci. 2015 Jun;145(2):273-82. doi: 10.1093/toxsci/kfv049. Epub 2015 Mar 4.
21 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
22 Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96.